SB202190 (FHPI)

Name: SB202190 (FHPI)
Brand: Selleck Chemicals
SKU: S1077
Rating: 5 (76 reviews)

For research use only.

Catalog No.S1077

76 publications

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Selleck's SB202190 (FHPI) has been cited by 76 publications

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815.e5

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )
Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )
Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

Targets

p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
50 nM	100 nM

In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. ^[2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. ^[3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). ^[4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. ^[6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	M3zTNGZ2dmO2aX;uJGF{e2G7	M3rVc\|I2KM7:TR?=	NHKyc24{OCCvaX6=	NHrOTVRFVVORwrC=	MXrheJRmdnWjdHXzJJRp\SCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25ib3[gbGJFNTJiaX6gdoV{eG:wc3n2[UB1dyCGQR?=	NWj2T\|VROjZ{MkOyOVE>
MDA-MB-231	MVjGeY5kfGmxbjDBd5NigQ>?	Mm\pNkDPxE1?	NWryNYJlOjRiaB?=		NH3mbplt\XO\|ZX7ld{BES0x{IHnu[JVkfGmxbjDifUBVVkcQsR?=	NX3OcoFsOjZzMEC4OFg>
rBMSCs	Mlq2SpVv[3Srb36gRZN{[Xl?	NYHXW3Q2OTBizszN	MlzYNk42KGh?		MX7k[ZBz\XO\|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCHUlugZY5lKHB\|OB?=	NEXaW28zPjB3M{K2Oi=>
MG63	MoDESpVv[3Srb36gRZN{[Xl?	NUXENmpWOTBxMkCvN\|Ah\|ryP	NHXNZ5ozPCCq		NWDEN3dGe2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgeIhmKGyndnXsJI9nKHCqb4PwbI9zgWyjdHXkJJA{QCCrbnT1Z4VlKGK7IFPkR4wzKGmwIHGgZ49v[2WwdILheIlwdiBvZHXw[Y5l\W62IH3hco5meg>?	Mlu1NlU6QTh\|MUK=
MG63	MVTBdI9xfG:\|aYOgRZN{[Xl?	NYGwVpJROTBxMkCvN\|Ah\|ryP	MnO1NlQhcA>?		NVy1cZlIe2mpbnnmbYNidnSueTDk[YNz\WG\|ZXSgeIhmKGGyb4D0c5NqeyC{YYTlJI9nKE2JNkOgbY5lfWOnZDDifUBE\EOuMh?=	MX6yOVk6QDNzMh?=
HTSMCs	MWTGeY5kfGmxbjDBd5NigQ>?	M1jsbVAvOS9zL{GwJO69VQ>?	MmH5NUBp		M1y1cYlvcGmkaYTl[EBEV1KPLUKtbY5lfWOnZDDIU{0yKHC{b4TlbY4hdGW4ZXzzJIFv\CCvUl7BJIV5eHKnc4Ppc44>	MmHGNlU6OjF2NkS=
MIA PaCa-2	MVHGeY5kfGmxbjDBd5NigQ>?	MljCNlDDqM7:TR?=	M3fRZVI1KGh?		MmTwdoVlfWOnZDDsZYN1[XSnIHHjZ5VufWyjdHnvckBqdiClb33ibY5ifGmxbjD3bZRpKGKxdHigNk1FTyCjbnSgSE1idGyxc3ZCpC=>	MXyyOVg5QDR6OR?=
MIA PaCa-2	NUjUd\|B3TnWwY4Tpc44hSXO\|YYm=	MmDoNlDDqM7:TR?=	M3qzRVI1KGh?		NHrXTJBz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=>	MUGyOVg5QDR6OR?=
BxPC-3	NXfsZoRkTnWwY4Tpc44hSXO\|YYm=	NHy3fGszOMLizszN	NXzpdJFjOjRiaB?=		NYXnd4o2emW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	NGDsbYszPTh6OES4PS=>
AsPC-1	MXTGeY5kfGmxbjDBd5NigQ>?	MkXNNlDDqM7:TR?=	NWf6WJY6OjRiaB?=		MWTy[ZN2dHS\|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?=	MlzrNlU5QDh2OEm=
MIA PaCa-2	M{[yeWZ2dmO2aX;uJGF{e2G7	M{XVNlIxyqEQvF2=	Ml23NlQhcA>?		M1\1[4VvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCge4hmdiClb33ibY5m\CC5aYToJIdtfWOxc3WgZY5idG:pcx?=	NUDvTWp1OjV6OEi0PFk>
MIA PaCa-2	NF3DdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvuR5lYOjEEoN88US=>	NWm5fmN2OiCq		M2TVfZNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NFfXUVUzPTh6OES4PS=>
BxPC-3	NVXj[\|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjzbFVxOjEEoN88US=>	MWmyJIg>		NH:xVHR{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MYmyOVg5QDR6OR?=
AsPC-1	NIXVdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfFZ3ozOMLizszN	M3\seVIhcA>?		MnTTd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	MWCyOVg5QDR6OR?=
HEY	NXnHUXlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnOyNlDDqM7:TR?=	M1TpbFIhcA>?		NGLwT\|B{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MkTCNlU5QDh2OEm=
OVCAR-3	MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjuOnNMOjEEoN88US=>	MXeyJIg>		NV[5OVhbe2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	M4C4ZlI2QDh6NEi5
SK-OV-3	NWLSWXpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLITnAzOMLizszN	NWnnVXFGOiCq		MoTZd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	M37EcVI2QDh6NEi5
MH7A	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mnz2NlQhcA>?		MkPtdoVqdm[xcnPld{B1cGViaX7obYJqfG:{eTDl[oZm[3S\|IH;mJHhCVg>?	NETSV2QzPTh4Mkm2Oi=>
MH7A	MWTBdI9xfG:\|aYOgRZN{[Xl?	NV;Gcng2OjVizszN	MlSzNlQhcA>?		MV7y[ZZmenOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpcoR2[2WmIHL5JHhCViCjbnSgZ4F2e2WmIHHwc5B1d3OrczDv[kBk\WyuczD2bYEh[WO2aY\heIlwdiCxZjDKUms>	MYeyOVg3Ojl4Nh?=
SCC25	MXTGeY5kfGmxbjDBd5NigQ>?	MYiyNEDPxE1?	NV\rUHg6OjRiaB?=		M1e4VIlv[3KnYYPld{BifXSxcHjh[5khdGW4ZXy=	M3zjd\|I2QDN2NECw
HaCaT	MoSySpVv[3Srb36gRZN{[Xl?	Mnu1OUDDvU1?	NU\IdXdUOjRiaB?=		MYLpcohq[mm2czDJSm4u\|rNvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	MoTMNlU5OzR\|NUO=
HaCaT	MUXGeY5kfGmxbjDBd5NigQ>?	MWW1JOK2VQ>?	M{LnXVI1KGh?		MWLpcohq[mm2czDJSm4u\|rFvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	NIPEUWwzPTh\|NEO1Ny=>
HPAEpiCs	MVjGeY5kfGmxbjDBd5NigQ>?	M2L3SlEwOy9zMDFOwG0>	M3fPUVEhcA>?		MmGwdoVlfWOnczDTNXAucW6mdXPl[EBKS0GPLUGgdJJwfGWrbjDhcoQhdVKQQTDlfJBz\XO\|aX;uJIFv\CCycn;tc5RmeiCjY4Tpeol1gQ>?	NVPIXGd5OjV5M{S5NFA>
HPAEpiCs	MYHGeY5kfGmxbjDBd5NigQ>?	MnvrNU8{NzFyIN88US=>	MmnTNUBp		M2rQWIlvcGmkaYTzJHMyWC2\|dHnteYxifGWmIFHreEBxcG:\|cHjvdplt[XSrb36gJOKh	NGLEO3gzPTd\|NEmwNC=>
HPAEpiCs	M2TqdGZ2dmO2aX;uJGF{e2G7	MmnDNU8{NzFyIN88US=>	NXe2R3JSOSCq		NX30TGFkcW6qaXLpeJMhWzGSIITpcYUu\GWyZX7k[Y51dHlic4TpcZVt[XSnZDDjMWp2diCyaH;zdIhwenmuYYTpc44>	MWmyOVc{PDlyMB?=
K562	MoOxSpVv[3Srb36gRZN{[Xl?	NITGW2wyOMLizszN	MV:xxsBp	Mn3pSG1UVw>?	Ml75bY5pcWKrdIOgdZVqdmGlcnnu[U1qdmS3Y3XkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	NFjZU4EzPTZ6NEC0Ny=>
PANC-1	M2LQV2Z2dmO2aX;uJGF{e2G7	M1rxOVExKM7:TR?=	NFrCcosyKGh?		MXXlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>?	NGPPdYgzPTZ\|MkKyNi=>
BxPC-3	M1HGZmZ2dmO2aX;uJGF{e2G7	NHnx[2wyOCEQvF2=	MYmxJIg>		MmjH[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB?	MXSyOVY{OjJ{Mh?=
K562	MVLGeY5kfGmxbjDBd5NigQ>?	M1T3SVAvOjVvMTFOwG0>	MmXpNlQhcA>?		MWjzeZBxemW\|c3XzJJJme3[ncnH0do9tNWmwZIXj[YQhUDKDWDDwbI9{eGixconsZZRqd25?	M4nXb\|I2PjF7M{my
THP-1	MYjGeY5kfGmxbjDBd5NigQ>?	MojGOUDDvU1?	Ml[3NkBp		MUPzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNic3XjdoV1cW:wIH;mJGlNNTIQsTDpcoR2[2WmIHL5JFI4V0iFaH;sJJBtfXNiRmPMMVHDqA>?	MUeyOVU6QDZ4MR?=
WB	M{X4SmZ2dmO2aX;uJGF{e2G7	M2PCRVIx6oDLzszNxsA>	MnvlN\|DjiImvaX6=		MlzE[IVkemWjc3XzJJRp\SCOUGOtJI9zKEyWQT3pcoR2[2WmIFnMMVYh[W6mIGTOSk3PucLicILv[JVkfGmxbh?=	MnH2NlU2OzB4OEK=
RAW 264.7	M2TNPWZ2dmO2aX;uJGF{e2G7	M2i0V\|ExyqEQvF2=	MVmzNQKBkW2rbh?=		NF\aZ3BqdmS3Y3XzJINp[XKjY4Tldol{fGmlII\hZ5VwdGG2aX;uJI9nKE:Fc9Mg	NFjiRXMzPTR4MUO5PS=>
RAW 264.7	M4rBbGZ2dmO2aX;uJGF{e2G7	NHjxZowyOMLizszN	M3O4VFMx6oDLbXnu		M1e1[YF1fGWwdXH0[ZMhfGinIHXm[oVkfHNib3[gU3BIKG:wIH;zeIVw[2yjc4SgdoV1emGldHnvci=>	MoPJNlU1PjF\|OUm=
HaCaT	NIHie5FHfW6ldHnvckBCe3OjeR?=	Mme4OFDDqM7:TR?=	MWmzMVI1KGh?	M{j4NWROW09?	MWLy[YR2[2W\|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>?	NHnDb2YzPTR\|NUS4OS=>
H9c2	MUnGeY5kfGmxbjDBd5NigQ>?	NEO4VJQ2OMLizszNxsA>	NX[0SWVrOTJiaB?=		M3XHVZJm\HWlZYOgUGRJKHKnbHXhd4Uh[W6mIF3NVEBtd3O\|	MlzBNlUzPDV6MUi=
HSCs	M{D3RmFxd3C2b4Ppd{BCe3OjeR?=	NGLVTpEzPSEQvF2=	MnnENlTDqGh?		MYTzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN?	MmDpNlQ6PjF7NUC=
THP-1	NY\GfGNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUG3NkBp	NXnQUpFnTE2VTx?=	MXPJR\|UxRTRwN988US=>	NWTEWI1mOjR6MUWwPFc>
MDDCs	M4LYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LMVVczKGh?	MW\EUXNQ	M2jVRWlEPTB{LkhOwG0>	M2DYZlI1QDF3MEi3
MDDCs	NITlN3FHfW6ldHnvckBCe3OjeR?=	MYewMVE2KM7:TR?=	MlnZOFghcA>?	NYDOT2NiTE2VTx?=	M3e4XpN2eHC{ZYPz[ZMhUU[QLd8xJIFv\CCLUD2xNEBxem:mdXP0bY9vyqB?	NWDGTZYyOjR6MUWwPFc>
MDDCs	NVLufnE2TnWwY4Tpc44hSXO\|YYm=	NGG2TnQxNTF3IN88US=>	NYjZWpFQPDhiaB?=	MVLEUXNQ	MmnLbY5pcWKrdIOgUWlRNTGjLDDNTXAuOWJiYX7kJHJCVlSHUzDwdo9lfWO2aX;u	NVi4OWNpOjR6MUWwPFc>
MDDCs	MWfGeY5kfGmxbjDBd5NigQ>?	NXn5PXlpOTBizszN	NUnENHRtOy53IHi=	NXLHdJpnTE2VTx?=	MWficI9kc3NiRVLPWkBIWCxiYoX0JI5wfCCYU2[gS{Bu\WSrYYTl[EBmdnS{eTDpcpRwKGi3bXHuJG1FTEO\|	NWXifZBlOjR6MUWwPFc>
macrophages	NVvmepNtTnWwY4Tpc44hSXO\|YYm=	M2nBVFHjiIoQvF2=	M172VlQvPeLCiXi=		NGX3bYVkd22ybHX0[Yx6KGmwaHnibZR{KE2WLVnJTU1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiTl[t{tpD	M1jaUlI1QDB6NkOz
PDL	MXfGeY5kfGmxbjDBd5NigQ>?	MoT0NlDDqM7:TdMg	M4rYVlMxKG2rbh?=	NHT6WHdFVVOR	NHnLfZF{cWewaX\pZ4FvfGy7IHnubIljcXS\|IITo[UB1\W6\|aXzlJIZwemOnLX3l[IlifGWmIFLNVE0zKGW6cILld5Nqd25?	NIP6SZQzPDV4MUC4NS=>
AGS	M3zXO2Z2dmO2aX;uJGF{e2G7	MmLZOUDPxE1?	MkPFN\|AhdWmw		M2jX[JN2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v	MoLpNlQ2PDd6N{i=
H520	MmrBSpVv[3Srb36gRZN{[Xl?	NXXPVG86OTEEoNM1US=>	Mn;kNUBp	NIr2UIRFVVOR	MXTk[YNz\WG\|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy\|	MU[yOFU{ODR5NR?=
H1703	MYTGeY5kfGmxbjDBd5NigQ>?	MX6xNOKhyrWP	MkjJNUBp	NWi3[VZvTE2VTx?=	NY\NT\|FF\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=>	NVexVXBZOjR3M{C0O\|U>
H520	MoPVSpVv[3Srb36gRZN{[Xl?	Mn;sNVDDqML3TR?=	M{X2XFEzKGh?	MUfEUXNQ	NUHxRpdWcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5	NYLTWZNXOjR3M{C0O\|U>
H1703	MUfGeY5kfGmxbjDBd5NigQ>?	NEXVbJMyOMLiwsXN	NWXrUXJuOTJiaB?=	NH2zfldFVVOR	NYjOdpY{cW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5	NYTBeGVCOjR3M{C0O\|U>
H520	NX;LZ45rTnWwY4Tpc44hSXO\|YYm=	M1Xx[FExyqEEtV2=	MXe2JIg>	NUHOeZJbTE2VTx?=	M2HreZNq\26rZnnjZY51dHliaX7jdoVie2W\|IITo[UBt\X[nbIOgc4YhfWKrcYXpeIlvNWOxbnr1[4F1\WRiTWPINkBqdiCyZX3leJJmgGWmLYTy[YF1\WUEoHPlcIwhdGmwZR?=	NHHPSpUzPDV\|MES3OS=>
H1703	MkHBSpVv[3Srb36gRZN{[Xl?	MoTPNVDDqML3TR?=	NFjwSXU3KGh?	M3\uO2ROW09?	MX7zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy\|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV?	NXPaOXVVOjR3M{C0O\|U>
MC3T3-E1	MX;GeY5kfGmxbjDBd5NigQ>?	NF;nRZIxNjNxMz:zNEDPxE1?	MkjBNUBp		MUfheJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25iaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	MWKyOFUxOjZ7Nh?=
MC3T3-E1	M4fxcWZ2dmO2aX;uJGF{e2G7	MkP5N\|Ah\|ryP	NULMeVloOSCq		MU\heJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	M2P1UFI1PTB{Nkm2
HUVECs	MVzGeY5kfGmxbjDBd5NigQ>?	MWixNOKhyrWP	NUPZTFM4OSCq		M37RbolvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIFPYR2wyKHC{b3T1Z5Rqd25?	NEnYWHEzPDR6N{m2OC=>
AGS	M3jYZWZ2dmO2aX;uJGF{e2G7	NI\LTWcyOMLiwsXN	NGPSRnA{OMLibXnu		NXzaUXlscW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i=	MYiyOFQ4QTZ6MR?=
MKN-45	MoHZSpVv[3Srb36gRZN{[Xl?	NXnD[YY4OTEEoNM1US=>	NWjIXG1POzEEoH3pci=>		MVHpcohq[mm2czDJUE0y\|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>?	MmHtNlQ1Pzl4OEG=
AGS	NG\4dlNHfW6ldHnvckBCe3OjeR?=	NVnC[3ZtOTEEoNM1US=>	M1jpb\|MxyqCvaX6=		NFy2cmdifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>?	NVr5b5NCOjR2N{m2PFE>
MKN-45	MXjGeY5kfGmxbjDBd5NigQ>?	NFPUZVgyOMLiwsXN	NI[0SGU{OMLibXnu		NHfadY9ifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>?	M2P3[FI1PDd7Nkix
AGS	NEWxZmpHfW6ldHnvckBCe3OjeR?=	NVLQV4g1OTEEoNM1US=>	NELU[3Y{OMLibXnu		M2XjfZNq\26rZnnjZY51dHliZHXjdoVie2W\|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w	MVKyOFQ4QTZ6MR?=
MKN-45	NUjCSWhPTnWwY4Tpc44hSXO\|YYm=	M3vCSFExyqEEtV2=	NEfQeHc{OMLibXnu		MV3zbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>?	NGHTeoszPDR5OU[4NS=>
DCs	MUHGeY5kfGmxbjDBd5NigQ>?	NIfEOYozOMLizszN	Mo[yNeKhcA>?		MWHk[YNz\WG\|ZYOgTWwuOTJicILv[JVkfGmxbh?=	MkL5NlQ1OzR4M{[=
HUVEC	M2jPeWZ2dmO2aX;uJGF{e2G7	MnjONlAh\|ryvwrC=	NWL0PYtGPSCq	NVPLeJVJTE2VTx?=	MorWdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO\|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?=	MkLwNlQyQDlyNkK=
A 549	MWjGeY5kfGmxbjDBd5NigQ>?	MXW1NEDPxE1?	MUGxJIg>		M2\4WYRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiSVytPOKh	M2LJN\|I1OTd7Nki4
H520	MnLFSpVv[3Srb36gRZN{[Xl?	M3vmNlUwOTBizszN	MUixJIg>	NWXkVnlqTE2VTx?=	M4fuOIRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs	Mk\tNlQyOzh7MEO=
H1703	NWiyc4hpTnWwY4Tpc44hSXO\|YYm=	MUC1M\|ExKM7:TR?=	M4jFOVEhcA>?	Mm\lSG1UVw>?	NVzTN2Jn\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw>	MUWyOFE{QDlyMx?=
H520	Mn[zSpVv[3Srb36gRZN{[Xl?	NVnMWXR5OTEEoNM1US=>	NVXV[2JrOTJiaB?=	NULrUXYyTE2VTx?=	M1ixUoRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	NXrt[okyOjRzM{i5NFM>
H1703	NIjURYtHfW6ldHnvckBCe3OjeR?=	MkXDNVDDqML3TR?=	NWDDNlBnOTJiaB?=	MoXmSG1UVw>?	Mmex[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC\|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM>	NVTEXm9bOjRzM{i5NFM>
MCF-7	M2TVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWqxNOKh\|ryP	NWfGXoxmOjUEoHi=		MofhbY5pcWKrdIOgeIhmKEOUMUC4MYlv\HWlZXSgZ4VtdCCmZXH0bC=>	Mo[4NlQyOjh6NUO=
HPAEpiCs	MYTGeY5kfGmxbjDBd5NigQ>?	NGTTXZkxNjFxMT:xNEDPxE1?	NV3kTpZxOSCq		M4H2VolvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPQUGEzyqCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25?	NW\mV2lrOjRyNkmxOVg>
podocytes	MoXjSpVv[3Srb36gRZN{[Xl?	MmH1NVDDqM7:TR?=	M1jwbFEhcA>?		M1i2N4lvcGmkaYTzJHRITs7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6TVHQT{BidmRiRYLrNU8zyqB?	MWiyOFA{PjJzMh?=
MCF-7	MULGeY5kfGmxbjDBd5NigQ>?	NH7VNnEyOMLizszN	NU\sUpNPOSCq	MlnOSG1UVw>?	NWLTZYgxemWmdXPld{B1cGViV1GtbY5lfWOnZDDwbI9{eGixconsZZRm\CCyM{igUWFRUw>?	M4jH[\|I1ODF7MEmw
MCF-7	NFrVWodHfW6ldHnvckBCe3OjeR?=	NUTqR\|ZLOTEEoN88US=>	Mn7zNlQhcA>?	MkfXSG1UVw>?	MXrpcoNz\WG\|ZYOgeIhmKFeDLXnu[JVk\WRiYYDvdJRwe2m\|	NIizPHczPDBzOUC5NC=>
HAPI	M1XtdGZ2dmO2aX;uJGF{e2G7	Mn3ONVAwOjBxNEFCpO69VQ>?	MnvyNUBp		Mkj0bY5pcWKrdIOgWGNFTC2rbnT1Z4VlKHB\|OD;KUmshVUGSSzDwbI9{eGixconsZZRqd25?	MX[yN\|k3QTF{MB?=
HAPI	NXf3[WdWTnWwY4Tpc44hSXO\|YYm=	M3K0NlIxyqEQvF5CpC=>	MnvHNUBp	NYW3OWI6TE2VTx?=	MWXheJRmdnWjdHXzJHRETERvaX7keYNm\CCjY4TpeoF1cW:wIH;mJIlPV1NiYX7kJJBzd2S3Y4Tpc44>	NWPVS2xTOjN7NkmxNlA>
HepG2	NIjGVXJHfW6ldHnvckBCe3OjeR?=	NHTiPHE{PTBibl2=	NELHSXkzPCCq		MoWwbY5pcWKrdIOgeIhmKGSnZ4XlcIlvNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDwN\|hOSVCN	M1TlflI{QTN\|MUm4
AGS	NUe4VFBKTnWwY4Tpc44hSXO\|YYm=	MVKxNOKh\|ryP	Ml\EN\|AhdWmw		MXzpcohq[mm2czDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiaX7obYJqfGmxbjDv[kBGWkt?	NYO5[mlNOjN6NUC5PVQ>
HepG2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTvNE02OCEQvF2=	MmfEOFghcA>?		Mnj2bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MYOyN\|gxPzVyOB?=
BEL7404	NWHUVZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOwMVUxKM7:TR?=	Mn7YOFghcA>?		M2iy[IlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MUKyN\|gxPzVyOB?=
HL7702	M{PjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnLdmIxNTVyIN88US=>	NWHxdolmPDhiaB?=		NETJSlVqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NV3xe4s4OjN6MEe1NFg>
HepG2	MnTESpVv[3Srb36gRZN{[Xl?	M1HB[\|AuPTBizszN	MmfvNlQhcA>?		M3fUU4lvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26\|dILlZY0heHKxdHXpcpMhVUGSS1HQT\|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NU\mW2FJOjN6MEe1NFg>
BEAS-2B	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7uNVAh\|ryP	NFfzVVg{OCCvaX6=		NYnyUnQ5emW4ZYLz[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgTGNK	MmjLNlM4QDRyM{S=
BEAS-2B	NHPneFREgXSxdH;4bZR6KEG\|c3H5	NX7Ye3NIOTBizszN	MojTN\|AhdWmw		M4Wwd4lvcGmkaYTl[EB1cGViaX7jdoVie2ViaX6gUGRJKGGwZDDJUE05KGW6cILld5Nqd25?	Ml3ZNlM4QDRyM{S=
BEAS-2B	NFXNVG9HfW6ldHnvckBCe3OjeR?=	MXyxNEDPxE1?	MknpN\|AhdWmw		NEnseJll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjZZNx[XOnLUOsJGJi\CCjbnSg[oF{	NYTLOFhpOjN5OESwN\|Q>
H9c2	NX7a[HplTnWwY4Tpc44hSXO\|YYm=	NILxNooxNjBzL{CuNU8yKM7:TR?=	M{nEW\|EhcA>?		NVzWdWM5[XS2ZX71ZZRmeyCWTl[t{tEucW6mdXPl[EBOVVBvOTDlfJBz\XO\|aX;uMEBuWk6DIHzleoVteyxiYX7kJJBzd22xdHXyJIFkfGm4aYT5	Mn;ENlM4PzR{NUK=
H9c2	M4DTNGZ2dmO2aX;uJGF{e2G7	MUexJO69VQ>?	MXixJIg>		NWL1b3J1emWmdXPld{BVVkZvzsGg[Ilz\WO2bImgd5RqdXWuYYTl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	NX\5dYtNOjN5N{SyOVI>
U937	NHfvVZpHfW6ldHnvckBCe3OjeR?=	M1vSZlExyqEQvF5CpC=>	NULENVRVOSCq		NYrhNmty[WK{b3fheIV{KHSqZTDjZYZn\WmwZTDl[oZm[3Rib36gUWtRNTFiYX7kJHBROkGlzsGgcXJPSSC2cnHud4NzcXC2aX;uZYwhdGW4ZXzz	Mn7sNlM4ODd\|OEe=
U937	M4SySWZ2dmO2aX;uJGF{e2G7	NGnZbHgyOMLizszNxsA>	Mn3XNUBp		MkfjZYJzd2ejdHXzJINi\m[naX7lMYlv\HWlZXSgUWtRNTFiZH;3ck1z\We3bHH0bY9vKGGwZDDQVFJC[87zIIXwMZJm\3WuYYTpc44>	NWrEUJVmOjN5MEezPFc>
U937	MYDGeY5kfGmxbjDBd5NigQ>?	NYT3OIU1OTEEoN88UeKh	MoTTNUBp		MULzeZBxemW\|c3XzJIMuUnWwIHHu[EBEWkWEIIDoc5NxcG:{eXzheIlwdiCrbjDjZYZn\WmwZT30doVifGWmIHPlcIx{yqB?	M4W1flI{PzB5M{i3
A549	NUW2eppzTnWwY4Tpc44hSXO\|YYm=	NHSzPZQxNjNxMz:zNEDPxE1?	MmrwNUBp		NGfr[ZB{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgRXRR\|rOVLX3l[IlifGWmIFPPXE0zKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCjbnSgdJJwdW:2ZYKgZYN1cX[rdIpCpC=>	NIe3N3kzOzZ6ME[3OC=>
A549	NF7jUWhHfW6ldHnvckBCe3OjeR?=	NXjS[nc2OTEEoN88UeKh	NFXKXGwxNTNyIH3pci=>		Mn3vbY5pcWKrdIOgRXRR\|rOVIHnu[JVk\WRicESyM5A1PCCPQWDLJIFv\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	MXiyN\|Y5ODZ5NB?=
A549	MUDGeY5kfGmxbjDBd5NigQ>?	NYH2VJZEOTEEoN88UeKh	NF3McG4yKGh?		M2fQeolvcGmkaYTzJGFVWM7\|UzDpcoR2[2WmIF7GMe67SiCyNkWgd5VjfW6rdDDwbI9{eGixconsZZRqd25iYX7kJG5HNc78QjDwdo9ud3SncjDhZ5Rqfmm2eR?=	NYqyNHpvOjN4OEC2O\|Q>
A549	Mnr1SpVv[3Srb36gRZN{[Xl?	NXviZnVQOTEEoN88UeKh	Mor1NUBp		MXPy[YR2[2W\|IFHUVO6{Wy2\|dHnteYxifGWmIHPQUGEzKHCqb4PwbI9zgWyjdHnvcuKh	M3nwXFI{PjhyNke0
A549	NFLOV2FHfW6ldHnvckBCe3OjeR?=	M2TsN\|ExyqEQvF5CpC=>	MVexJIg>		M4r1XZJm\HWlZYOgRXRR\|rOVLXXubIFv[2WmIHXufplu[XSrYzDhZ5Rqfmm2eTDv[kBkWEyDMtMg	MlLCNlM3QDB4N{S=
PC12	NH;3d4dHfW6ldHnvckBCe3OjeR?=	NE\rUoMyOC9{MD:0NEDPxE1?	NVHGPJNVOcLiaB?=		NYDtbIVOcW6qaXLpeJMhUk6NIHHu[EBxOzh?	MViyN\|U5PDN3Nx?=
HK-2	M1jCcGFxd3C2b4Ppd{BCe3OjeR?=	NHu3WZYzOMLizszN	M3;oNFI1KGh?		MYHpcohq[mm2czDFVmsh[W6mIICzPG1CWEt?	Ml;BNlM2PDNzNUG=
H9c2	NXHHOWc3TnWwY4Tpc44hSXO\|YYm=	NEjZSHoyyqEQvF2=	MYSxJIg>		NYjtNY92emWmdXPld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCvUl7BJIxmfmWuczDhcoQheHKxbX;0[ZIh[WO2aY\peJk>	MknHNlM{PTN4OUm=
H9c2	NEDGVplHfW6ldHnvckBCe3OjeR?=	NXvofGxYOcLizszN	NYTyUGNNOSCq		M{n2cpJm\HWlZYOgWG5HNc7zLXXubIFv[2WmIFHQMVEheHKxbX;0[ZIh[WO2aY\peJk>	NGOzOmgzOzN3M{[5PS=>
H1650	MVPGeY5kfGmxbjDBd5NigQ>?	M{\L[\|ExyqEQvF5CpC=>	MVexJIg>	NWruV2pZTE2VTx?=	M1vROIRm[3KnYYPld{Bjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yx{KG:oIFXSR2MyKGmwIIDhZ4xqfGG6ZXyt[Zhxd3OnZNMgZ4VtdHN?	NGPPeG8zOzJ{OE[5Oi=>
H1703	NVvJWmJXTnWwY4Tpc44hSXO\|YYm=	MXqxNOKh\|ryPwrC=	NXz3dW9tOSCq	MnHBSG1UVw>?	MoTN[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR\|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>?	M13y[\|I{OjJ6Nkm2
H1650	M1;STGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzZZmhWOTEEoN88UeKh	MlXFNUBp	NITMOmlFVVOR	NG[xfHpmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[3m2b4TvfIlkcXS7	NVXUb\|ZzOjN{Mki2PVY>
H1703	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrINVRPOTEEoN88UeKh	NHXFS2syKGh?	M3qw[GROW09?	M{PIT4VvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl?	NUS4fWZYOjN{Mki2PVY>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. ^[5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. ^[8]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-³³P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-³³P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research: ^[2]	- Collapse Cell lines: Jurkat, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~50 μM Incubation Time: 24 hours Method: Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG Dosages: 12.5 μg Administration: Administered via i.d. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SB202190 (FHPI) SDF

Molecular Weight	331.34
Formula	C₂₀H₁₄N₃OF
CAS No.	152121-30-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	OC1=CC=C(C=C1)C2=NC(=C([NH]2)C3=CC=NC=C3)C4=CC=C(F)C=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Selective p38 MAPK Inhibitor

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Ralimetinib (LY2228820)

Ralimetinib (LY2228820) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)